Immunome (IMNM) Non-Current Debt (2020 - 2021)

Immunome (IMNM) reported Non-Current Debt of $134000.0 for Q1 2021, little changed quarter-over-quarter from $134000.0 in Q4 2020.

Immunome (IMNM) Non-Current Debt (2020 - 2021) Analysis & Trends

Immunome has reported Non-Current Debt for 2 years, with the latest figure at $134000.0 in Q1 2021.

For the quarter ending Q1 2021, Non-Current Debt changed N/A year-over-year to $134000.0; the trailing twelve-month figure through Mar 2021 stood at $134000.0 (changed N/A YoY), and the FY2020 full-year result was $134000.0, changed N/A from the prior year.
Non-Current Debt for Q1 2021 stood at $134000.0, roughly flat from $134000.0 in the prior quarter.
The five-year high for Non-Current Debt was $195000.0 in Q3 2020, with the low at $134000.0 in Q4 2020.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Non-Current Debt (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-	-
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-	-
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn	319.10 Mn
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-	-
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-	-
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-	-
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn	-
9	Abivax	91.96 Bn	91.96 Bn	-	-
10	Immunome	2.12 Bn	1.54 Bn	-	-

Download Data